Index Entries

Jarrah Alabkal, Alexander D. Rebchuk, Daniel Lyndon, and Nikkie Randhawa
December 16, 2021
Cureus
University of British Columbia

"Abstract: In response to the coronavirus disease 2019 (COVID-19) pandemic, rapid development, clinical testing, and regulatory approval of vaccines occurred. The tozinameran COVID-19 vaccine is the first mRNA vaccine approved for use in humans. Transverse myelitis is a rare inflammatory disorder of the spinal cord that is associated with traditional vaccinations. There are rare case reports describing an association between mRNA vaccines and transverse myelitis. Herein, we describe a case of transverse myelitis following mRNA vaccination. A healthy 26-year-old woman developed saddle anesthesia, numbness, and allodynia in the S1-S4 distribution within three days of receiving the first dose of tozinameran COVID-19 vaccine."

document
adverse events,COVID-19,mRNA,neurological disorders,vaccines